Results for tag: "Non Alcoholic Steatohepatitis Drug"

Non Alcoholic Steatohepatitis (NASH) Drug market is a subset of the Liver and Kidney Disorders Drugs market. NASH is a chronic liver disease caused by the accumulation of fat in the liver, leading to inflammation and scarring. It is a major cause of cirrhosis and liver failure. The NASH Drug market is driven by the increasing prevalence of NASH, rising awareness of the disease, and the availability of new treatments. The NASH Drug market is segmented by drug class, including biologics, small molecules, and others. Biologics are the most widely used drugs for NASH, as they target specific pathways involved in the disease. Small molecules are also used to treat NASH, as they are more cost-effective and have fewer side effects. The NASH Drug market is highly competitive, with many companies developing new treatments. Some of the major players in the market include Gilead Sciences, Intercept Pharmaceuticals, Allergan, Novartis, and Genfit. Show Less Read more